1. Lipoyl-Homotaurine Derivative (ADM_12) Reverts Oxaliplatin-Induced Neuropathy and Reduces Cancer Cells Malignancy by Inhibiting Carbonic Anhydrase IX (CAIX)
- Author
-
Barbara Richichi, Lorenzo Di Cesare Mannelli, Alexandra Louka, Oscar Francesconi, Cristina Nativi, Marco Fragai, Andrea Angeli, Vito Calderone, Roberta Gualdani, Giuseppina Comito, Paola Chiarugi, Carla Ghelardini, Alessio Nocentini, Paola Gratteri, Francesco Tadini-Buoninsegni, and Claudiu T. Supuran
- Subjects
0301 basic medicine ,Organoplatinum Compounds ,Taurine ,Stereochemistry ,Antineoplastic Agents ,03 medical and health sciences ,chemistry.chemical_compound ,In vivo ,Cell Line, Tumor ,Neoplasms ,Pancreatic cancer ,Drug Discovery ,medicine ,Humans ,Carbonic Anhydrase IX ,Carbonic Anhydrase Inhibitors ,TRPA1 Cation Channel ,Antagonist ,Peripheral Nervous System Diseases ,Drug Synergism ,medicine.disease ,In vitro ,Oxaliplatin ,Pancreatic Neoplasms ,030104 developmental biology ,chemistry ,Homotaurine ,Cell culture ,Cancer cell ,Cancer research ,Molecular Medicine ,medicine.drug - Abstract
Oxaliplatin (OXA) is a valuable and largely used cancer drug which induces a serious and intractable neuropathy. The lipoyl-homotaurine derivative (ADM_12) reverts in vivo OXA-induced neuropathy, and it is an effective antagonist of the nociceptive sensor channel TRPA1. Unprecedentedly, this safe analgesic showed a synergy with OXA in vitro and proved to inhibit CA IX, a relevant therapeutic target, clearly interfering with pancreatic cancer cells' aggressiveness.
- Published
- 2017
- Full Text
- View/download PDF